- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Healthy potentially undervalued
Hong Kong Pharmaceuticals & Biotech Healthy potentially undervalued
Results
12
Companies which are potentially undervalued and in an acceptable financial position.
12 companies
Genscript Biotech
Market Cap: HK$29.4b
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
1548
HK$12.99
7D
-6.9%
1Y
-3.3%
China Resources Pharmaceutical Group
Market Cap: HK$29.8b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.74
7D
2.6%
1Y
-9.5%
United Laboratories International Holdings
Market Cap: HK$17.5b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$8.66
7D
2.0%
1Y
-41.8%
3SBio
Market Cap: HK$40.9b
An investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally.
1530
HK$15.98
7D
-7.4%
1Y
-17.8%
Duality Biotherapeutics
Market Cap: HK$18.1b
A clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others.
9606
HK$187.50
7D
-10.4%
1Y
-10.3%
Everest Medicines
Market Cap: HK$10.1b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$29.04
7D
1.0%
1Y
-38.8%
InnoCare Pharma
Market Cap: HK$22.6b
A biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
9969
HK$10.76
7D
-4.1%
1Y
-5.9%
Grand Pharmaceutical Group
Market Cap: HK$18.2b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials.
512
HK$5.15
7D
-1.3%
1Y
-39.9%
China Medical System Holdings
Market Cap: HK$25.5b
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
867
HK$10.55
7D
2.0%
1Y
0.9%
Shanghai Junshi Biosciences
Market Cap: HK$33.0b
A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.
1877
HK$17.60
7D
-13.2%
1Y
-17.8%
RemeGen
Market Cap: HK$58.6b
A biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.
9995
HK$72.40
7D
-8.3%
1Y
53.1%
WuXi Biologics (Cayman)
Market Cap: HK$135.1b
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil.
2269
HK$32.42
7D
0.1%
1Y
30.2%